Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is a successful and growing company with a focus on musculoskeletal solutions and enabling technologies. Despite competition and potential risks, their solid financial profile and increasing demand for their spinal robotic technology make them a strong investment choice. The company has shown strong revenue growth and profit margins, especially in their international spine business, and is actively expanding their sales force to further drive growth. However, investors should keep an eye on potential risks and the company's relatively short history since its founding in 2003.

Bears say

Globus Medical is facing challenges in maintaining its revenue growth and profitability, as evidenced by a decline in its base adjusted EBITDA margin in the last quarter. The company's reliance on the US market also poses a risk, as the medical device industry is highly regulated and exposed to product recalls. Additionally, while the launch of new products such as Excelsius3D imaging shows potential for sales growth, it also faces competition from larger players like Medtronic, who hold a 40% market share in this segment.

Globus Medical (GMED) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 13 analysts, Globus Medical (GMED) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.